A retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who have chronic kidney disease were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2018
Price : $35 *
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=4755) presented at the Digestive Disease Week 2018.
- 14 Apr 2018 Results (n=4755) presented at The International Liver Congress 2018.
- 14 Apr 2018 Results (n=4755) assessing the effect of acid-reducing agents use on SVR presented at The International Liver Congress 2018